Exploring advanced genomic and immunoinformatics techniques for identifying drug and vaccine targets against SARS-CoV-2 DOI Creative Commons
Syed Luqman Ali, Awais Ali,

Waseef Ullah

et al.

Journal of Genetic Engineering and Biotechnology, Journal Year: 2024, Volume and Issue: 22(4), P. 100439 - 100439

Published: Nov. 16, 2024

The coronavirus that causes serious acute respiratory syndrome. Severe syndrome 2 (SARS-CoV-2) is still a major problem in public health and biomedicine. Even if there no cure for it, the infection progressing naturally, only time optimal treatment choices, such as doxycycline, work at beginning of infection. Our project structured into two critical parts: first focuses on identification potential drug targets, second vaccine design, both aimed exploring new ways to treat disease. Initially, cytoplasmic proteins identified through subtractive analysis underwent comprehensive evaluation targeting, focusing metabolic pathways, homology prediction, drugability assessment, essentiality, protein-protein interactions. Subsequently, surface rigorous assessment allergenicity, antigenicity, physiochemical attributes, conserved regions, protein interactions, B T cell epitopes. Molecular docking immunological simulation analyses were then employed develop characterize multi-epitope vaccine, integrating findings from aforementioned evaluations. Findings study point six therapeutic targets SARS-CoV-2, each which involved distinct process. reverse vaccinology suggested following could be used candidates: sp|P05106, sp|O00187, sp|Q9NYK1, sp|P05556, sp|P09958, sp|Q9HC29. Four named SARS-COV-2-, C1, C2, C3, C4 was designed by utilizing different adjuvants eighteen overlapped epitopes predicted top ranked protiens. Based immune study, exhibited adequate immune-reactivity favorable encounters with toll-type receptors (TLR4, TLR8, HLA, etc ACE), Among them SARS-COV-2-C2 showed best binding affinity all receptors. this game-changer quest medication effectively combat SARS-CoV-2. It necessary do additional experimental analyses, nevertheless.

Language: Английский

Adoptive transfer of natural killer cells in therapeutic treatment of COVID-19 patients DOI Creative Commons
Abdulaziz Alamri

Egyptian Journal of Medical Human Genetics, Journal Year: 2025, Volume and Issue: 26(1)

Published: Feb. 22, 2025

Abstract Background Natural killer (NK) cells are crucial constituents of innate immunity, playing a vital role in the early defense against viral infections and cancer. Their antiviral capabilities stem from direct cytotoxic activity infected immunoregulatory functions that modulate adaptive immune responses. In context Coronavirus disease (COVID-19), NK contribute to controlling replication limiting excessive inflammatory Aims This review highlights mechanisms underlying cell-mediated activity, focusing on their interactions with severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2). We discuss potential sources for adoptive transfer therapy, critical factors influencing therapeutic efficacy, considerations clinical translation COVID-19 treatment. Methods Various cell therapy discussed, including peripheral blood, cord genetically engineered cells. Key efficacy safety cell-based therapies analyzed, cytokine modulation, subset selection, delivery methods. Conclusion Understanding influence success can inform design more effective immunotherapies patients. Strategies improving function, such as genetic modification optimizing protocols, highlighted enhance outcomes. Graphical neutralize SARS-CoV-2 by releasing granules, inhibiting replication, modulating inflammation. They originate engineering. Therapeutic strategies include transfer, optimized delivery. Inflammation is controlled, reducing

Language: Английский

Citations

0
A Stable mRNA-Based Novel Multi-Epitope Vaccine Designs Against Infectious Heartland Virus by Integrated Immunoinformatics and Reverse Vaccinology Approaches DOI
Awais Ali, Syed Luqman Ali

Viral Immunology, Journal Year: 2025, Volume and Issue: unknown

Published: March 24, 2025

The Heartland virus (HRTV) is a tick-borne human pathogenic phlebovirus that primarily causes leukopenia and thrombocytopenia. It transmitted by Amblyomma americanum type of tick, is, notable for their aggressive biting behavior, affinity hosts, high prevalence. Developing vaccines or immunizations against HRTV gaining importance as public-health preventive strategy. current study was planned to prioritize multi-epitope stable mRNA vaccine model from lead B-cell T-cell epitopes (with IC50 < 100 nM) proteome following advanced immunoinformatics approaches. Model constructs were designed linking the most potent, nonallergenic along with incorporation ribosomal protein adjuvant immune response enhancement. immunogenic potential coding molecule examined via molecular docking toll-like receptors followed normal mode analysis dynamics simulations-based energy minimization, stability, flexibility assessments. A robust, circular precursor multi-epitopes incorporating Kozak consensus sequence, start codon, essential elements such MHC class I trafficking domain (MITD), tPA, Goblin 5′ 3′ Untranslated Region (UTRs), poly (A) tail. This strategic amalgamation ensures elevated immunogenicity predicts promising HRTV. simulation predicted capable elicit cell-mediated humoral responses. examine experimentally its safety features.

Language: Английский

Citations

0
Subtractive proteomics and reverse-vaccinology approaches for novel drug targets and designing a chimeric vaccine against Ruminococcus gnavus strain RJX1120 DOI Creative Commons

Hou Dingding,

Sher Muhammad,

Irfan Manzoor

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 14, 2025

Mediterraneibacter gnavus , also known as Ruminococcus is a Gram-positive anaerobic bacterium that resides in the human gut microbiota. Notably, this plays dual roles health and disease. On one side it supports nutrient metabolism essential for bodily functions on other contributes to development of Inflammatory Bowel Disease (IBD) gastrointestinal disorders. R. strain RJX1120 an encapsulated has been linked develop IBD. Despite advances made its role homeostasis, limited information available strain-specific virulence factors, metabolic pathways, regulatory mechanisms. The study such aspects crucial make microbiota-targeted therapy understand implications host health. A multi-epitope vaccine against was designed using reverse vaccinology-based subtractive proteomics approach. Among 3,219 proteins identified RJX1120, two critical virulent antigenic proteins, Single-stranded DNA-binding protein SSB (A0A2N5PT08) Cell division ATP-binding FtsE (A0A2N5NK05) were screened potential targets. predicted B-cell T-cell epitopes from these immunological properties antigenicity, allergenicity, solubility, MHC binding affinity, toxicity. Epitopes chosen cross-linked suitable spacers adjuvant vaccine. Structural refinement construct revealed 95.7% amino acid residues located favored regions, indicating high-quality structural model. Molecular docking analysis demonstrated robust interaction between Toll-like receptor 4 (TLR4), with energy −1277.0 kcal/mol. results molecular dynamics simulations further confirmed stability vaccine-receptor complex under physiological conditions. In silico cloning yielded GC content 48% Codon Adaptation Index (CAI) value 1.0, optimal expression system. These indicate possibility candidate prevention -associated diseases. However, experimental validation required confirm immunogenicity protective efficacy.

Language: Английский

Citations

0
Exploring advanced genomic and immunoinformatics techniques for identifying drug and vaccine targets against SARS-CoV-2 DOI Creative Commons
Syed Luqman Ali, Awais Ali,

Waseef Ullah

et al.

Journal of Genetic Engineering and Biotechnology, Journal Year: 2024, Volume and Issue: 22(4), P. 100439 - 100439

Published: Nov. 16, 2024

The coronavirus that causes serious acute respiratory syndrome. Severe syndrome 2 (SARS-CoV-2) is still a major problem in public health and biomedicine. Even if there no cure for it, the infection progressing naturally, only time optimal treatment choices, such as doxycycline, work at beginning of infection. Our project structured into two critical parts: first focuses on identification potential drug targets, second vaccine design, both aimed exploring new ways to treat disease. Initially, cytoplasmic proteins identified through subtractive analysis underwent comprehensive evaluation targeting, focusing metabolic pathways, homology prediction, drugability assessment, essentiality, protein-protein interactions. Subsequently, surface rigorous assessment allergenicity, antigenicity, physiochemical attributes, conserved regions, protein interactions, B T cell epitopes. Molecular docking immunological simulation analyses were then employed develop characterize multi-epitope vaccine, integrating findings from aforementioned evaluations. Findings study point six therapeutic targets SARS-CoV-2, each which involved distinct process. reverse vaccinology suggested following could be used candidates: sp|P05106, sp|O00187, sp|Q9NYK1, sp|P05556, sp|P09958, sp|Q9HC29. Four named SARS-COV-2-, C1, C2, C3, C4 was designed by utilizing different adjuvants eighteen overlapped epitopes predicted top ranked protiens. Based immune study, exhibited adequate immune-reactivity favorable encounters with toll-type receptors (TLR4, TLR8, HLA, etc ACE), Among them SARS-COV-2-C2 showed best binding affinity all receptors. this game-changer quest medication effectively combat SARS-CoV-2. It necessary do additional experimental analyses, nevertheless.

Language: Английский

Citations

2